ValGenesis, Inc., a company involved in enterprise validation lifecycle management systems (VLMS), reported that a UK-based global contract research organization (CRO), selected ValGenesis VLMS to digitize its corporate validation process.

The company provides services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Its fast-growing businesses include a suite of specialist pharmaco vigilance solutions and global Phase I-IV clinical development and trial management services.

The depth and breadth of functionality within ValGenesis VLMS and the Design Manager Module that supports the software development lifecycle (SDLC) was seen as a “game changer” by the company. They see ValGenesis VLMS as pivotal to their digital transformation journey because of its ability to support both current computer system validation (CSV) operations and future computer software assurance (CSA), while simultaneously supporting internal agile SDLC management within a single digital validation tool.

“This is a noteworthy win for ValGenesis as we onboard yet another pharma giant in Europe,” said Steve Reynolds, chief revenue officer at ValGenesis. “With the ValGenesis VLMS, our client can eliminate wasted time on “over validation” and improve overall quality, collaboration, and efficiency. By choosing our SaaS-based platform to manage validation lifecycle processes across their company, they will help themselves and their clients meet stringent validation requirements while accelerating drug development and manufacture in Europe and across the globe.”